ArticleDiscover oncology2025
A bibliometric study on microenvironment-mediated drug resistance in interventional liver cancer treatment.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroenvironment-driven drug resistance is a principal barrier to durable response after transarterial chemoembolisation, ablation or radioembolisation for hepatocellular carcinoma, yet the global structure of scholarship linking these domains remains undefined. This bibliometric analysis mapped 25-year publication trends, thematic evolution and collaboration networks at the intersection of interventional oncology, tumour microenvironment and therapeutic resistance.
methodsWeb of Science Core Collection was searched (1 January 2000–31 December 2024) for records simultaneously referencing liver cancer, interventional therapy, microenvironmental descriptors and resistance terms. After dual-review screening, 939 articles and reviews were retained. Annual output, citation impact and Bradford-zone distributions were generated with bibliometrix 4.2.1. Bradford-zone analysis refers to the distribution of journal productivity, with journals in the first zone representing core literature, and those in subsequent zones reflecting peripheral or niche studies. This method helps assess the concentration of research in key journals and identifies areas of growth in the literature; co-authorship, journal-coupling and keyword-co-occurrence networks were rendered in VOSviewer 1.6.20. Workflow reproducibility was confirmed on a 5% subsample and by comparing fractional with full counting.
resultsYearly publications rose from two in 2000 to 130 in 2024, amassing 36 095 citations (mean 38.4 per item). Output spikes in 2013, 2019 and 2021 paralleled seminal reports on hypoxia-driven angiogenesis, CAF activation, and COVID-19-related endothelial dysfunction. The pathophysiological mechanisms of COVID-19-induced endothelial injury, including cytokine-mediated endothelial dysfunction, have been implicated in compromising loco-regional therapies, contributing to resistance mechanisms that affect the efficacy of embolic treatments. China produced 47.3% of documents and sat at the nexus of global collaboration, with prominent links to the United States, Japan and South Korea. Cancer Research, Hepatology and Journal of Hepatology led citation rankings. Keyword overlays revealed a chronological shift from procedure-centric terms to microenvironmental and immunologic nodes—“angiogenesis”, “immune checkpoint”, “nanoparticles”—after 2017. Trend-topic mapping documented a transition from device optimisation toward mechanism-informed combination regimens incorporating anti-VEGF or PD-1 blockade.
conclusionResearch on microenvironment-mediated resistance in interventional liver-cancer therapy has expanded rapidly and pivoted toward molecularly targeted, immune-augmented strategies, driven chiefly by high-volume Chinese centres and trans-Pacific partnerships. Priorities now include single-cell analytics, radiomics-guided adaptive embolisation and multinational trials of combination therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.